Iovance Biotherapeutics (Commercial)
Iovance Biotherapeutics is committed to developing commercially available cell therapies for patients with solid tumors and hematologic malignancies utilizing autologous Tumor Infiltrating Lymphocytes (TIL) that amplify and rejuvenate the body’s own immune response to eradicate cancer.
Our unique TIL technology platform, has enabled us to generate scalable, personalized, cell therapies that are currently in clinical studies for multiple cancers including metastatic melanoma, cervical cancer, head and neck cancer, non-small cell lung cancer, and chronic lymphocytic leukemia.